Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

HIV-1 Env-specific fully human monoclonal antibody

A specific, antibody technology, applied in the direction of antibodies, antiviral agents, antitumor drugs, etc., to achieve the effect of reducing immunogenicity, good application prospects, and improving antiviral effect

Active Publication Date: 2015-08-12
STATION OF VIRUS PREVENTION & CONTROL CHINA DISEASES PREVENTION & CONTROL CENT
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These studies all suggest that if we find more neutralizing antibodies and apply them in combination, it is possible to prevent infection, and it is also possible to clear more viruses during treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • HIV-1 Env-specific fully human monoclonal antibody
  • HIV-1 Env-specific fully human monoclonal antibody
  • HIV-1 Env-specific fully human monoclonal antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0011] The whole human monoclonal antibody preparation and antibody characteristic analysis process of the present invention is divided into two parts: using B cell culture and RT-PCR method to obtain antibody gene and antibody expression; and antibody characteristic analysis.

[0012] 1 Antibody gene screening and antibody expression and purification

[0013] 1.1 Isolation and purification of memory B cells

[0014] After testing the plasma neutralizing activity of HIV-1 infected patients, the infected patients with better plasma neutralizing activity were screened out, and 20ml of EDTA anticoagulated whole blood samples were taken after obtaining the informed consent of the infected patients. Add 20ml of fresh anticoagulated whole blood into a human lymphocyte separation tube (purchased from Shenzhen Dakowei Co., Ltd.) at a rate of 5ml / tube, centrifuge at 2200r / min for 15min, and absorb the white lymphocyte layer in the middle, which is human peripheral blood mononuclear cel...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of gene engineering, and particularly relates to a human monoclonal antibody with an anti-HIV Env specificity. The antibody molecules have a neutralizing activity and antibody-dependent cell-mediated cytotoxicity (ADCC) on HIV-1. The antibodies can be applied singly or combinedly to prevent infection, and further can eliminate more viruses possibly in treatment; moreover, HIV-1 monoclonal antibodies can be further applied in diagnosis and treatment of HIV-1 infection.

Description

technical field [0001] The invention belongs to the field of biomedicine. The present invention relates to multiple strains of HIV envelope protein (Env) specific fully human monoclonal antibodies, and these antibody molecules have neutralizing activity and antibody-dependent cell-mediated cytotoxicity (ADCC) to HIV-1. Background technique [0002] During the process of virus infection of the host, a large number of virus-specific antibodies are produced in the host body, and these antibodies mainly clear the virus through neutralization and ADCC. Virus infection of cells can be summarized as three main steps of attachment, fusion and nucleocapsid entry. Neutralizing antibodies can act on every link of attachment, fusion and nucleocapsid entry into the cell, and can also prevent the release of assembled nucleocapsid and virus. In addition, antibodies can also form macromolecular aggregates that are cleared by cell phagocytosis by cross-linking with virus particles that are...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/10C12N15/13C12N15/85C12N5/10A61K39/42A61K48/00A61P31/18A61P35/00A61P25/28
Inventor 余双庆曾毅管永军徐柯汪慧敏冯霞
Owner STATION OF VIRUS PREVENTION & CONTROL CHINA DISEASES PREVENTION & CONTROL CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products